Health topic
Obesity and weight management
What is this condition?
A chronic, relapsing disease characterized by excess adiposity and associated metabolic risk.
Where peptide medicines or pathways fit
GLP-1 and dual incretin agonists are approved for chronic weight management in selected adults.
Approved versus investigational
Evidence in women by life stage
Obesity trials for semaglutide and tirzepatide enrolled majorities of women. STEP-1 enrolled about 1,961 participants (~63% female) and SURMOUNT-1 enrolled 2,539 (~67.5% female). Prespecified sex subgroup analyses are reported, but the trials were powered for overall efficacy and life-stage details are missing.
Representation and analysis gaps
Menopausal status, contraceptive use, menstrual-cycle phase, and long-term pregnancy outcomes are not consistently reported.
Current guideline context
Guidelines recognize obesity as a chronic disease and recommend comprehensive management; specific guidance on selecting among incretin therapies by sex is not established.
What we do not cover
We do not provide weight-loss protocols, dosing, or off-label optimization guidance.
Related audits
Sources
Primary records
- peer reviewed article · New England Journal of Medicine · 2022-07-21
Phase 3 trial of tirzepatide in adults with obesity or overweight without diabetes (NCT04184622).
- peer reviewed article · New England Journal of Medicine · 2021-03-18
Phase 3 trial of semaglutide 2.4 mg for chronic weight management.
Secondary context
- guideline
Repository or society guideline source; verify the current edition and issuing organization.
- regulatory review
FDA resource summarizing demographic participation in drug trials.
Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.